Omega-3 And Alzheimer’S Risk — The Strongest Evidence We Have
Quick Read Omega-3 fatty acids, particularly two types called DHA and EPA found in fish and supplements, appear to play
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Mild cognitive impairment (MCI) affects millions of people over 50 and significantly increases the risk of dementia, but it sits in a window where nutrition and supplements may still help. Researchers have identified several supplements with genuine evidence backing them. B vitamins like folic acid and B12 show the strongest and most consistent results across multiple studies, particularly for memory and attention. Omega-3 fatty acids (fish oil) also show real but modest benefits across large populations. Vitamin D appears promising and is especially important because deficiency is common, particularly in the UK.
Beyond these, Pycnogenol (an extract from pine bark) ranked highest in a recent comparison of botanical treatments, and a whey protein supplement containing specific ingredients showed meaningful improvements in one well-designed trial. Regular multivitamins didn’t prevent MCI development in a large three-year study, but they did appear to slow decline in those who developed it. Popular options like ginkgo biloba have mixed evidence, while probiotics show interesting promise but need more research.
The honest limitation is that most studies are small, last only 12 months when cognitive changes take years to develop, and use different testing methods, making firm conclusions difficult. What works best is probably a combination: B vitamins plus omega-3s plus vitamin D as a foundation, alongside lifestyle factors like diet quality, exercise and sleep. Supplements appear to work best as part of a broader brain health approach rather than as standalone solutions.
Verdict: Several supplements have genuine evidence for slowing cognitive decline in mild cognitive impairment, with B vitamins and omega-3s most well-supported, but they work best as part of overall healthy lifestyle choices rather than replacements for them.
What if the window of greatest opportunity for protecting your brain isn’t after a diagnosis of dementia, but years before, in that quieter, more ambiguous zone called mild cognitive impairment? Most people assume cognitive decline is either something that happens to other people, or something that, once started, is unstoppable. But a growing body of research is telling a more nuanced, and more hopeful, story. MCI affects millions of adults over 50, and while it doesn’t always progress to dementia, it significantly increases the risk. The question researchers have been asking for decades is this: can targeted nutrition and supplementation slow, or even reverse, that progression? The answer, it turns out, is complicated. Some supplements have genuine, meaningful evidence. Others are hyped far beyond what the science supports. And a few are genuinely surprising. Here’s what the research actually shows, no exaggeration, no false comfort, and no hiding the gaps.
*At Vitacuity, we’ve analysed over 1.77 million research papers and selected the most relevant studies for this topic. What follows reflects the current weight of that evidence.*
Before we get into the supplements, it’s worth understanding what MCI actually is. Mild cognitive impairment sits in the grey zone between normal age-related forgetfulness and dementia. Someone with MCI might notice they’re slower to recall names, struggle to follow a complex conversation, or find that planning and problem-solving feel harder than they used to. It’s measurable, doctors use tools like the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Examination (MMSE) to detect it, but it doesn’t yet interfere significantly with daily life [1].
That distinction matters enormously for supplements research, because the evidence for nutritional interventions is much stronger at the MCI stage than it is for established dementia. The brain is still highly active, synapses are still forming and reforming, and the biological mechanisms that supplements can influence, inflammation, oxidative stress, neuronal membrane integrity, neurotransmitter production, are still responsive [7]. This is the window. And it’s why what you do in your 40s, 50s and 60s may matter more than almost anything else.
The mechanisms by which nutrition supports brain function are actually well understood. Your brain is roughly 60% fat by dry weight, and its neuronal membranes are continuously being broken down and rebuilt. That process requires raw materials: omega-3 fatty acids, choline, B vitamins, and other micronutrients act as the building blocks and cofactors for maintaining healthy synaptic connections [7]. Meanwhile, oxidative stress, the accumulation of cellular damage from free radicals, accelerates brain ageing, and many nutrients act as antioxidants or support the body’s own antioxidant systems [6]. When you’re deficient in key nutrients, these processes are compromised. And in older adults, deficiencies are far more common than most people realise [1].
If there is a single category of supplement with the most consistent evidence across MCI research, it is the B vitamins, particularly folate (folic acid, or vitamin B9), vitamin B6, and vitamin B12. And the mechanism makes biological sense.
Elevated homocysteine, an amino acid that accumulates when B vitamin status is low, is strongly associated with brain atrophy and cognitive decline. B vitamins, particularly folate and B12, are essential for the metabolic pathway that clears homocysteine from the body. When these vitamins are insufficient, homocysteine builds up, and the brain pays a price [9].
A 2024 meta-analysis of 16 randomised controlled trials found that folic acid supplementation showed a standardised mean difference (SMD) of 1.21 (95% CI: 0.87–1.55) for global cognitive function in MCI patients, a meaningful effect size by the standards of cognitive research. Interestingly, folic acid alone appeared to outperform combined B vitamin formulas: folic acid plus B12 produced an SMD of 0.71, and folic acid combined with DHA produced an SMD of 0.58. The study also found that vitamins as a class significantly improved memory function (SMD = 2.55, P = 0.001) and attention (SMD = 3.14, P = 0.004) [2].
A 2023 systematic review of previous reviews, drawing on 12 primary studies of B vitamins in MCI, concluded that the evidence was mostly positive, though limited by small sample sizes [9]. An earlier 2018 systematic review found that folic acid supplementation (in one study of 266 participants) and folic acid alone (in a second study of 180 participants) produced some of the most consistent improvements in memory performance across all dietary interventions examined [10].
There is an important caveat worth noting: one 2024 systematic review found that positive effects of B vitamins were only observed in non-aspirin users who also had high omega-3 fatty acid plasma levels [1]. This suggests B vitamins don’t work in isolation, they may need adequate omega-3 status to work effectively on the brain. It’s a detail that rarely makes the headlines, but it matters practically.
Evidence grade: Promising to strong. Multiple RCTs and meta-analyses support B vitamins, especially folic acid, for cognitive function in MCI. The interaction with omega-3 status and aspirin use adds nuance. Not settled science, but among the best-supported nutritional interventions available.
Omega-3 fatty acids, specifically EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are the other category of supplement with the most research behind them. DHA is structurally critical to neuronal membranes, particularly in the synaptic regions where brain cells communicate. EPA plays a more anti-inflammatory role. Both matter [8].
A major 2025 overview of systematic reviews, covering nine systematic reviews incorporating 14 RCTs and representing 26,881 participants aged 40 and over, found a statistically significant but modest improvement in MMSE scores with omega-3 supplementation (effect size: 0.16; 95% CI: 0.01–0.32) [3]. An effect size of 0.16 is small, we’ll be honest about that, but when applied across nearly 27,000 participants, and when considered as part of a broader lifestyle approach, it represents real signal, not noise.
The 2024 meta-analysis found that PUFAs (polyunsaturated fatty acids, which include omega-3s) improved memory function (SMD = 0.65, P < 0.001) and attention (SMD = 2.98, P < 0.001) in MCI patients specifically [2]. An earlier 2019 systematic review of 10 RCTs found that 10 out of 14 trials reviewed showed positive outcomes on at least one cognitive domain, including working memory, executive function, verbal memory, short-term memory and perceptual speed [8].
Why the inconsistency across trials? The 2019 review identified several likely culprits: different doses of EPA and DHA, different durations of supplementation (some as short as three months, others over two years), and critically, the baseline cognitive status of participants. People with existing omega-3 deficiency appear to benefit most. Healthy, well-nourished adults with already adequate omega-3 levels show smaller effects [8]. This helps explain why some trials show clear benefits and others show nothing.
Evidence grade: Promising. Multiple RCTs across large combined populations show consistent, modest benefits in MCI. The effect isn’t dramatic, but it is real and replicable. DHA and EPA both appear to contribute, particularly to memory and attention.
Vitamin D keeps appearing across the MCI literature in ways that are hard to ignore. A 2024 systematic review of 33 primary studies concluded that vitamin D supplementation would “most likely reduce cognitive decline, dementia, or Alzheimer’s disease”, placing it alongside probiotics and PUFAs as the most promising interventions, and ahead of vitamins A, C, E and the B complex [1].
The 2024 meta-analysis similarly found that vitamin D may improve global cognitive function, memory and attention in MCI patients, though the authors were careful to note the evidence remains preliminary and further trials are needed [2]. A 2023 review of reviews also flagged vitamin D as a potentially beneficial intervention for cognitive subdomains, while acknowledging that the number of primary studies is still small [9].
The biological rationale is sound: vitamin D receptors are found throughout the brain, and vitamin D is involved in neuroprotection, neuroplasticity, and the clearance of amyloid, the protein associated with Alzheimer’s disease pathology. Deficiency is extraordinarily common in the UK, particularly in winter months and in adults over 50 [1].
Evidence grade: Promising. The pattern across reviews is consistent, and the biological mechanism is well-established. The human trial data is not yet definitive, we need larger, longer RCTs. But given that deficiency is common, safe supplementation at normal doses (1,000–4,000 IU daily) is a logical approach.
Here’s one that might genuinely surprise you. A 2025 network meta-analysis, using a Bayesian framework to compare 18 different botanical interventions across 19 trials and 4,956 participants, found that Pycnogenol (a standardised extract of French maritime pine bark) showed the most significant effect on cognitive function in MCI, with a Surface Under the Cumulative Ranking Curve (SUCRA) score of 98.8% for cognitive improvement and 100% for improving daily living activities [4].
Pycnogenol is a potent antioxidant and anti-inflammatory compound. Its proposed mechanisms include improving cerebral blood flow, reducing oxidative stress, and supporting endothelial function, all of which matter for brain health [4]. The same analysis found that *Cosmos caudatus* extract ranked highest for psychological wellbeing in MCI (SUCRA: 98.9%), though this is a less familiar supplement and the evidence base is thinner [4].
A 2018 systematic review also found clinical evidence supporting several botanicals for cognitive decline, including Ginkgo biloba, Bacopa monnieri, resveratrol, and saffron (*Crocus sativus*), though effect sizes varied and study quality was often limited [12].
Evidence grade: Promising for Pycnogenol specifically; mixed to early-stage for most other botanicals. The network meta-analysis is an important piece of evidence, but heterogeneity across trials means we should interpret with caution. Ginkgo biloba, despite its popularity, has more mixed results, a 2018 dietary interventions review found no significant effect on progression from MCI to dementia in one trial of 482 participants [10].
The gut-brain axis, the biochemical conversation between your microbiome and your brain, is one of the more exciting emerging areas of neuroscience. And it has real implications for MCI.
The 2024 systematic review placed probiotics alongside vitamin D and PUFAs as the three most likely interventions to reduce cognitive decline, dementia, or Alzheimer’s disease, a notable finding given how little attention probiotics receive in conversations about brain health [1]. A 2023 review of reviews, drawing on four primary probiotic studies in MCI, also rated the evidence as mostly positive [9].
The proposed mechanism involves the gut microbiome’s influence on neuroinflammation, production of neurotransmitter precursors, and the vagus nerve pathway between gut and brain. When the microbiome is disrupted, which is common with age, inflammatory signals increase and these protective pathways are compromised [1].
Evidence grade: Promising but early. Only four primary studies were included in the most relevant review, and the field is young. The signal is interesting enough to watch closely, and the safety profile of quality probiotics is excellent.
One of the more intriguing recent findings comes from a 2025 randomised controlled trial, 107 participants with MCI, mean age 63, over 12 months. Participants were given 15g per day of a whey protein powder rich in milk fat globule membrane (MFGM), taurine, and B vitamins, or a placebo.
The results were notable: the active group showed a mean MoCA score increase of 3.23 points (95% CI: 2.17–4.30) versus 1.42 points in the placebo group, with a significant between-group difference of 1.81 points (95% CI: 0.32–3.30). The Digit Symbol Substitution Test, a measure of processing speed and attention, also showed a significant between-group difference of 2.72 points (95% CI: 0.20–5.23). Side effects were minimal and comparable between groups [5].
A MoCA improvement of 1.81 points is clinically meaningful in a population with MCI, this isn’t a marginal rounding error. That said, this is a single trial, the sample size is modest, and the supplement contains multiple active ingredients (MFGM, taurine, and B vitamins), so it’s not possible to isolate which component drove the benefit [5].
Evidence grade: Promising. A well-designed single RCT with meaningful results. The multi-ingredient nature of the intervention makes it hard to disentangle the active components. Replication in larger trials is needed.
The COSMOS-Mind trial, published in 2023, is one of the largest and most rigorous trials to examine multivitamin-mineral supplementation and cognitive outcomes, 2,262 participants, randomised, double-blind, over three years [15].
The headline finding was cautious: multivitamin-mineral supplementation did not significantly reduce the *incidence* of MCI or dementia over three years. But the detail is more interesting. When participants taking multivitamins *did* develop MCI, their global cognition scores (p = 0.03) and executive function scores (p < 0.001) were significantly higher than placebo converters, and they had declined less in the year leading up to diagnosis (p = 0.03 for global cognition; p = 0.004 for executive function). The researchers described this as "cognitive resilience", the multivitamin didn't prevent MCI, but it appeared to soften the landing [15].
The statistical power was acknowledged as low for the incidence analysis, so we should be careful not to over-interpret either the positive or the null findings [15].
Evidence grade: Promising for cognitive resilience; conflicted for incidence reduction. The COSMOS-Mind trial is important, large, rigorous and real-world. The resilience finding is genuinely interesting and warrants follow-up research.
Several reviews have flagged flavonol supplementation as showing benefit for specific cognitive subdomains in MCI. A 2018 systematic review found improvements in memory with flavonol supplementation in a trial of 90 participants [10]. A 2023 review of reviews noted that blueberries, grape juice, and cocoa flavanols may improve individual cognitive subdomains, while cautioning that sample sizes were small and more studies are needed [9].
Interestingly, the COSMOS-Mind trial found no significant benefit from cocoa extract specifically over three years, which moderates the optimism somewhat [15].
The proposed mechanisms, reduced neuroinflammation, improved cerebral blood flow, antioxidant activity, are biologically plausible, and the broader polyphenol literature in plant and animal studies is substantial [12]. But the human trial evidence in MCI remains limited.
Evidence grade: Early stage to promising. The signal is interesting, the safety is excellent, but robust RCT evidence in MCI remains thin.
The honest truth about MCI supplementation research is that, despite real progress, there are significant gaps that prevent firm clinical recommendations for most interventions.
The heterogeneity problem. Nearly every systematic review in this area flags it: the studies use different cognitive tests, different dosages, different durations, different populations, and different definitions of MCI. This makes direct comparison almost impossible and pooled effect sizes less reliable [1][2][9].
Sample sizes are too small. Most individual RCTs in this field involve under 200 participants. That’s not enough to draw definitive conclusions, particularly when cognitive outcomes are multi-dimensional and take years to manifest meaningfully [10][14].
Duration is rarely long enough. Most trials run for 12 months or less. Cognitive decline develops over decades. A 12-month trial tells us something, but it may not capture whether an intervention genuinely alters long-term trajectory [3][8].
The interaction question. The finding that B vitamins only worked in non-aspirin users with high omega-3 levels is a fascinating clue that supplements may not work in isolation, they may require other conditions to be met [1]. We don’t yet have good data on how these interactions play out across different populations.
Genotypic differences. Some research has found that individual genetic variation, for example, APOE4 genotype, which significantly increases Alzheimer’s risk, may influence how people respond to certain supplements. The current evidence base hasn’t yet mapped these interactions in detail [1].
We don’t know who benefits most. Does baseline deficiency matter? Does age of starting intervention matter? Does it make a difference whether your MCI is amnestic (memory-focused) or non-amnestic? The literature currently can’t answer these questions with confidence [9].
Let’s think about this practically. You’re in your 40s, 50s or 60s. You’re paying attention to your brain health, which is already a sensible and evidence-based instinct. What should you actually do?
Start with the B vitamins. Folic acid (folate) and B12 have the most consistent evidence across multiple meta-analyses and systematic reviews. They’re water-soluble, which means excess is excreted in urine, there’s no meaningful toxicity risk at standard doses. They’re inexpensive. And the mechanism, clearing homocysteine and supporting neuronal function, is well understood. Supplement daily. If you’re not eating a diet rich in leafy greens, legumes and animal products, you’re very likely not getting optimal amounts from food alone.
Add omega-3s. The evidence isn’t dramatic, but it’s consistent across a large body of research covering nearly 27,000 participants. DHA and EPA at doses typically studied (around 1–2g combined per day) are safe, well-tolerated, and address a real gap in most Western diets, which are chronically low in oily fish. The interaction with B vitamins is another reason to take both together.
Take vitamin D seriously. If you live in the UK, you are statistically very likely to be deficient between October and April at minimum. Vitamin D deficiency is common, testing is impractical for most people on a routine basis, and supplementation at 1,000–4,000 IU is safe for virtually everyone. The cognitive evidence is promising and the broader health evidence is substantial. This is one of the most straightforward supplementation decisions you can make.
Consider Pycnogenol. It’s less well-known than the others, but the 2025 network meta-analysis result was striking, ranking it first among 18 botanical interventions for cognitive function in MCI. Look for standardised maritime pine bark extract. It’s safe, well-tolerated, and deserves more attention than it currently receives.
Don’t overthink the rest. Ginkgo biloba, despite its global popularity, has mixed evidence in MCI. Probiotics are interesting but still early-stage for cognitive applications. Cocoa flavanols are promising but the COSMOS-Mind trial should temper expectations. A quality multivitamin-mineral is reasonable insurance, not a cure, but the COSMOS-Mind “resilience” finding is a legitimate signal worth noting.
And remember the bigger picture. The research consistently frames supplements as *complementary* to lifestyle strategies, not replacements for them. Diet quality, physical activity, sleep optimisation, and cognitive engagement all show up in the same systematic reviews as meaningful contributors to brain health [3][9]. The supplements work best in a body that’s also being looked after in other ways.
One sensible, practical approach: a daily B complex, omega-3s, vitamin D, and a good antioxidant source (whether that’s Pycnogenol, or a diet genuinely rich in colourful plants). That’s not a medical prescription. It’s what a well-informed friend who has read the research would suggest, with the honest acknowledgement that we’re working with promising, not settled, science.
Your brain built everything you are. It deserves the same level of thoughtful investment you’d give to anything else you care deeply about.
[1] Supplementation and Mitigating Cognitive Decline in Older Adults With or Without Mild Cognitive Impairment or Dementia: A Systematic Review (2024). DOI: 10.3390/nu16203567 | https://pubmed.ncbi.nlm.nih.gov/39458561/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11509913/
[2] Effects of vitamins and polyunsaturated fatty acids on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials (2024). DOI: 10.1007/s00394-024-03324-y | https://pubmed.ncbi.nlm.nih.gov/38300291/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11139751/
[3] Omega-3 Polyunsaturated Fatty Acids and Cognitive Decline in Adults with Non-Dementia or Mild Cognitive Impairment: An Overview of Systematic Reviews (2025). DOI: 10.3390/nu17183002 | https://pubmed.ncbi.nlm.nih.gov/41010527/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472900/
[4] Comparative efficacy and safety of botanical drugs for mild cognitive impairment: a systematic review and network meta-analysis (2025). DOI: 10.3389/fphar.2025.1657169 | https://pubmed.ncbi.nlm.nih.gov/41333026/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12665759/
[5] Effect of a 12-mo intervention with whey protein powder on cognitive function in older adults with mild cognitive impairment: a randomized controlled trial (2025). DOI: 10.1016/j.ajcnut.2024.11.019 | https://pubmed.ncbi.nlm.nih.gov/39571910/
[6] Dietary supplements for cognitive impairment (2017). https://pubmed.ncbi.nlm.nih.gov/29171642/
[7] Rationale and clinical data supporting nutritional intervention in Alzheimer’s disease (2014). https://pubmed.ncbi.nlm.nih.gov/24635394/
[8] Omega-3 fatty acids and cognitive decline: a systematic review (2019). DOI: 10.20960/nh.02496 | https://pubmed.ncbi.nlm.nih.gov/31215788/
[9] Dietary pattern, food, and nutritional supplement effects on cognitive outcomes in mild cognitive impairment: a systematic review of previous reviews (2023). DOI: 10.1093/nutrit/nuad013 | https://pubmed.ncbi.nlm.nih.gov/37027832/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563860/
[10] Effect of dietary interventions in mild cognitive impairment: a systematic review (2018). DOI: 10.1017/S0007114518002945 | https://pubmed.ncbi.nlm.nih.gov/30409231/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679717/
[11] Activities, bioavailability, and metabolism of lipids from structural membranes and oils: Promising research on mild cognitive impairment (2018). https://pubmed.ncbi.nlm.nih.gov/30016644/
[12] Botanicals and phytochemicals active on cognitive decline: The clinical evidence (2018). https://pubmed.ncbi.nlm.nih.gov/29289576/
[13] Supplementing cognitive aging: a selective review of the effects of ginkgo biloba and a number of everyday nutritional substances (2010). https://pubmed.ncbi.nlm.nih.gov/20054730/
[14] A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment (2023). DOI: 10.1186/s13643-023-02301-6 | https://pubmed.ncbi.nlm.nih.gov/37592293/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433666/
[15] Impact of multivitamin-mineral and cocoa extract on incidence of mild cognitive impairment and dementia: Results from the COcoa Supplement and Multivitamin Outcomes Study for the Mind (COSMOS-Mind) (2023). DOI: 10.1002/alz.13078 | https://pubmed.ncbi.nlm.nih.gov/37035889/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562510/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Omega-3 fatty acids, particularly two types called DHA and EPA found in fish and supplements, appear to play
Quick Read Vitamins are organic compounds your body cannot make enough of on its own. They act as molecular tools
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.
